Dr. William Cohn is the chief medical officer for BiVACOR, a medical device company creating the first total artificial heart. Photo via TMC

It's hard to understate the impact Dr. William Cohn has had on cardiovascular health as a surgeon at the Texas Heart Institute or on health care innovation as the director of the Center for Device Innovation at the Texas Medical Center. However, his role as chief medical officer of BiVACOR might be his most significant contribution to health care yet.

The company's Total Artificial Heart is unlike any cardiovascular device that's existed, Cohn explains on the Houston Innovators Podcast. While most devices are used temporarily for patients awaiting a heart transplant, BiVACOR's TAH has the potential to be a permanent solution for the 200,000 patients who die of heart failure annually. Last year, only around 4,000 patients were able to receive heart transplants.

"Artificial hearts historically have had bladders that ejected and filled 144,000 times a day. They work great for temporary support, but no one is suggesting they are permanent devices," Cohn says on the show.

The difference with BiVACOR's device is it abandons the bladder approach. Cohn explains that as assist pumps evolved — something his colleague, Dr. Bud Frasier, had a huge impact on — they featured new turbine and rotor technology. Daniel Timms, BiVACOR's founder and CTO, iterated on this technology beginning when he was a postdoctoral student at Queensland University of Technology in Australia.

"BiVACOR is the first artificial heart that leverages what we learned from that whole period — it has no bladders, it has no valves. It has one moving part, and that moving part is suspended in an electromagnetic field controlled by a computer and changed thousands of times a second," Cohn says. "It will never wear out, and that's why we think it's the world's first total artificial heart."

The company is seeing momentum, celebrating its first successful human implantation last month. The device was used for eight days on a patient at Baylor St. Luke’s Medical Center before the patient received a heart transplant.

Cohn says that BiVACOR has plans to use the TAH as "bridge-to-transplant" device in several other surgeries and expects to get FDA approval for that purpose in the next three to four years before working toward clearance for total artificial heart transplants.

Cohn has worked to support medical device startups at CDI at TMC for the seven years it has existed — first under Johnson and Johnson and then under TMC when it took the program over. He describes the center and its location as the ideal place for developing the future of health care, with Houston rising up to compete with regions known for medical device success — both coasts and Minnesota.

"Being in the shadow of the largest medical center on the planet — 106,000 employees show up there every 24 hours," Cohn says, "if you want to innovate, this is the place to do it."

Revisiting a conversation with Dr. Joseph Rogers, president and CEO of the Texas Heart Institute, on the Houston Innovators Podcast. Photo via texasheart.org

Play it back: How this Houstonian is leading heart health innovation

HOUSTON INNOVATORS PODCAST EPISODE 246

Heart health innovation is at a major moment in history — and Houston is at the center of it.

Last summer, Dr. Joseph Rogers, president and CEO of the Houston-based Texas Heart Institute, joined the Houston Innovators Podcast to share how he came to be at the helm of THI, as well as the incredible technologies the institute is working on to address heart failure, a global epidemic affecting at least 26 million people worldwide, 6.2 million adults in the U.S.

This month, one of THI’s technologies reached a major milestone. BiVACOR, a Houston company successfully implanted the company's first Total Artificial Heart in a human. The device was implanted in the patient on July 9. Eight days later, a donor heart became available and was transplanted into the patient, removing the TAH, establishing the device as a successful bridge-to-heart-transplant solution for patients, THI reported.

In addition to this breakthrough in health tech, THI is focused on addressing Cardiometabolic Syndrome at a new conference on Friday, August 23, in Houston. The full-day symposium will take place in collaboration with Arianna Huffington, the founder and CEO of Thrive Global. Dr. Rogers is co-directing the program with Dr. Stephanie Coulter, medical director for THI Center for Women’s Heart & Vascular Health.


In the episode, Rogers explains why he's bullish on Houston and THI leading heart health innovation alongside other health care organizations — nonprofits, universities, local government — to collaborate in ways never been done before. And THI is dedicated to this mission.

"We should act as a convener," Rogers says. "Houston is the place to do this.

"The reason I think this is such an important community to address this problem is it's the most diverse city in the United States. And I've never lived anywhere or heard of another city that I was so convinced believed they could do anything they set their minds to. It's about making the community aware of the problem and a potential solution — and then working on trying to solve it," he continues. "But I think all of the pieces are here to show the world how to do this at a community level."

BiVACOR and The Texas Heart Institute have celebrated a major milestone in the future of heart health. Photo courtesy of BiVACOR

Houston medical device startup implants artificial heart in first human patient

big win

Heart health tech company BiVACOR and The Texas Heart Institute announced that they successfully implanted the company's first Total Artificial Heart in a human at Baylor St. Luke’s Medical Center in the TMC.

The milestone is part of an FDA-approved early feasibility study that will test the safety and performance of the TAH device, which is based on a magnetically levitated rotor that takes over functions of a failing heart while a patient is awaiting a heart transplant, according to a statement from the organizations.

The "bridge-to-transplant" device could support an active adult male, as well as many women and children suffering from severe biventricular heart failure or univentricular heart failure.

"With heart failure remaining a leading cause of mortality globally, the BiVACOR TAH offers a beacon of hope for countless patients awaiting a heart transplant,” Dr. Joseph Rogers, president and CEO of THI and national principal investigator on the research, says in a statement. “We are proud to be at the forefront of this medical breakthrough, working alongside the dedicated teams at BiVACOR, Baylor College of Medicine, and Baylor St. Luke’s Medical Center to transform the future of heart failure therapy for this vulnerable population.”

BiVACOR received approval from the FDA for the early feasibility study in late 2023 and has four other patients enrolled in the study. At the time the study was approved, 10 hospitals were enrolled as possible sites.

“I’m incredibly proud to witness the successful first-in-human implant of our TAH. This achievement would not have been possible without the courage of our first patient and their family, the dedication of our team, and our expert collaborators at The Texas Heart Institute ... our TAH brings us one step closer to providing a desperately needed option for people with end-stage heart failure who require support while waiting for a heart transplant. I look forward to continuing the next phase of our clinical trial,” Daniel Timms, PhD, founder and CTO of BiVACOR, adds.

About 100,000 patients suffering from severe heart failure could benefit from BiVACOR’s artificial heart, the company says. Globally, only about 6,000 heart transplants are performed each year, while 26 million people worldwide are affected by heart failure.

BiVACOR was founded in 2008 and maintains its headquarters in Houston, along with offices in Huntington Beach, California, and Brisbane, Australia.

To date, the company has raised nearly $50.8 million, according to CB Insights. The company raised $18 million in 2023, and $22 million in 2021.

Earlier this year, BiVACOR named a new CEO in Jim Dillon, a longtime executive in the medical device sector.

Last summer, Rogers joined the Houston Innovators Podcast to share his excitement with THI's innovations.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

10 most-promising energy tech startups named at annual Houston event

top companies

Investors from around the world again identified the most-promising energy tech startups at the Rice Alliance for Technology and Entrepreneurship's annual event.

"The recognition that Houston is the epicenter of energy transition is growing. It's something we are championing as much as possible so that the world can know exactly what we're doing," Paul Cherukuri, chief innovation officer at Rice University says at the 21st annual Energy Tech Venture Forum.

The event took place during the inaugural Houston Energy and Climate Startup Week, and nearly 100 startups from 23 states and seven countries pitched investors Wednesday, September 11, and Thursday, September 12. At the conclusion of the event, the investors decided on 10 companies deemed "most promising" from the presentations.

This year's selected companies are:

  • Revterra, a Houston-based company innovating within kinetic battery technology to enable faster and cleaner electric vehicle charging.
  • From Austin, 360 Mining is a modular data center provider for the oil and gas producers.
  • New York company Andium is a centralized and optimized operations platform for large energy companies.
  • Elementium Materials, a local Katy-based company, created its battery technology that originated out of MIT.
  • Splight is a San Mateo, California-based technology platform that provides real-time operational data based on inverter-based resources assets.
  • Los Angeles-based Mitico, one of the Rice Alliance Clean Energy Accelerator's class 4 participants, provides services and equipment for carbon capture through its granulated metal carbonate sorption technology.
  • From Cambridge, Massachusetts, Osmoses is changing the way molecular gas separations are performed within the chemical, petrochemical, and energy industries.
  • Rice Alliance Clean Energy Accelerator class 4 participant CORROLYTICS, based in Houston, has a corrosion detection and monitoring technology. The company also won over the crowd and secured the People's Choice win too.
  • Ardent, based in New Castle, Delaware, has developed a membrane technology for point-source carbon capture.
  • New Haven, Connecticut-based Oxylus Energy produces an alternative fuel from converting CO2 into green methanol.

Last year, investors named its selection of most-promising companies at Rice.

"We have a responsibility as a city to lead energy transition," Cherukuri continues. "A lot of the investments we're making at Rice are going to change the world."

Scientists use Houston rainwater to explore origins of life on Earth

let it rain

A flask of Houston’s rain helped answer a long-running question about the origin of cellular life.

The solution is proposed by two University of Houston scientists, William A. Brookshire Department of Chemical Engineering (UH ChBE) former grad student Aman Agrawal (now a postdoctoral researcher at University of Chicago’s Pritzker School of Molecular Engineering) and Alamgir Karim, UH Dow Chair and Welch Foundation Professor of chemical and biomolecular engineering, and director of both the International Polymer & Soft Matter Center and the Materials Engineering Program at UH. They were joined by UChicago PME Dean Emeritus Matthew Tirrell and Nobel Prize-winning biologist Jack Szostak in an article published last week in Scientific Advances.

For two decades, scientists like Szostak have hypothesized that RNA fragments were the first components of life to form in the Earth’s primordial seas 3.8 million years ago. Although DNA is an essential component of cellular life, it can’t fold proteins, making it unlikely to be the initial starting point. Since RNA can fold proteins, it could have been the catalyst for cellular growth and evolution.

The problem is that seawater molecules allow RNA to bond and change too quickly, often within minutes. Rapid dissipation means no segregation of material, and thus no evolution. Szostak himself proved in 2014 that regular seawater doesn’t allow RNA fragments to form the membranes necessary for cellular life.

Then along comes Agrawal. He wasn’t looking into the origin of life. He was an engineer studying the properties of complex liquids for his doctorate. Karim was his thesis adviser and introduced Agrawal to Tirrell, who brought up the RNA problem over a lunch and some theories about how if the water was distilled it may have solved it. Where would you get distilled water 3.8 billion years ago?

“I spontaneously said ‘rainwater,’” says Karim. “His eyes lit up and he was very excited at the suggestion. So, you can say it was a spontaneous combustion of ideas or ideation.”

Using RNA samples from Szostak, they saw that distilled water increased the differences in exchange rate between samples from minutes to days, long enough for the RNA to begin mutation.

Distilled lab water is nothing like prehistoric rain, though. Luckily, a typical Houston downpour occurred during the research. Agrawal and fellow UH graduate student, Anusha Vonteddu ran outside with beakers to collect some. The samples again formed meshy walls, separating the RNA and possibly showing how life began from these fragments billions of years ago.

“The molecules we used to build these protocells are just models until more suitable molecules can be found as substitutes,” Agrawal said. “While the chemistry would be a little bit different, the physics will remain the same.”

------

This article originally ran on CultureMap.